Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
3
Not yet recruiting, industry sponsors, Endocrinology and women's health, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed188
3 trials
Showing 1 to 3, recently updated first.
- PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine CorrelatesNot yet recruiting
Antev Ltd.Industry
NCT07914062 · 84 participants (planned) · Start Feb 2027 · Primary completion Dec 2029
Drug: Teverelix DP; Teverelix DP and 2 more · For: Endometriosis Pelvic; Endometriosis Ovaries; Premenopausal and 3 more
- Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone MassPivotal-lookingNot yet recruiting
Transcenta Therapeutics (Hangzhou) Co., Ltd.Industry
NCT07806331 · 110 participants (planned) · Start Oct 31, 2026 · Primary completion Apr 30, 2027
Drug: Denosumab; Placebo · For: Postmenopausal Osteoporosis; Low Bone Mass
- A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)Pivotal-lookingNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07450001 · 128 participants (planned) · Start Mar 6, 2026 · Primary completion Jul 18, 2028
Drug: GenSci134 Injection; Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) · For: Pediatric Growth Hormone Deficiency
Sites: Wuhan, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.